News

Here's what is coming soon to NeurologyLive.

The director of the Massachusetts General Hospital ALS Care Center discussed the greatest needs in ALS research and why focusing on genetics can play a big role into understanding the disease course.

The chief medical officer at SanBio discussed how the investigational agent SB623 is being studied in TBI and stroke, with future planned studies in Alzheimer disease.

Study results suggest that fewer than 10% of the more than 2000 migraine episodes analyzed were associated with increased levels of perceived stress.

Study data showed that 43% of patients with obstructive sleep apnea were referred to sleep specialist physicians for ongoing management by a primary care provider.

The chief scientific officer of QurAlis discussed how QRA-244 is more specific and potent than retigabine, a treatment currently in clinical studies.

Neurology News Network for the week ending February 6, 2021.

The director of the Parkinson’s Disease and Movement Disorder Program at Emory University School of Medicine shared his perspective on the research and development of Parkinson therapies.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 5, 2021.

The RAISE trial will examine the proportion of patients with refractory status epilepticus who experience status cessation within 30 minutes of initiation of intravenous ganaxolone.

The annual meeting will now take place October 25–28, 2021 at the Rosen Shingle Creek in Orlando, Florida.

Researchers compared CMH rates in PSEN1, PSEN2, and APP mutation carriers and noncarriers of dominantly inherited Alzheimer disease.

The director of the Dartmouth Epilepsy Program provided an overview of some of the critical unmet needs within ongoing epilepsy research following the recent AES Annual Meeting.

Researchers also observed that PAP machines from ISPs were used for a longer median duration than those from DMEs.

Observation of pain freedom at 30 minutes was more accurate than the observation of relief at 30 minutes in predicting pain freedom at 2 hours.

The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine provided thoughts on why cognitive care and sleep disorder care should crossover more often.

Researchers found that time between assessments was the only predictor of PACC score differences.

Earlier AD diagnosis with the AlzoSure assay could potentially make it feasible to initiate disease-modifying therapies much earlier in the disease process.